Amy Calhoun

Amy Calhoun

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2018 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
YZYuri A. Zarate
Yuri A. Zarate
CHConstance Hicks-Smith
Constance Hicks-Smith
CGCarol Greene
Carol Greene
MAMary‐Alice Abbott
Mary‐Alice Abbott
VSVictoria M. Siu
Victoria M. Siu
WCWendy K. Chung
Wendy K. Chung

8 January 2016 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
KHKaren Ho
Karen Ho
SSSarah T South
Sarah T South
ALAmanda Lortz
Amanda Lortz
CHCharles H Hensel
Charles H Hensel
MSMallory R Sdano
Mallory R Sdano
ABAgatino Battaglia
Agatino Battaglia
Background Wolf–Hirschhorn syndrome (WHS) is a contiguous gene deletion syndrome involving variable size deletions of the 4p16.3 region. Seizures are frequently, but not always, associated with WHS. We hypothesised that the size and location of the deleted region may correlate with seizure presentation. Methods Using chromosomal microarray analysis, we finely mapped the breakpoints of copy number variants (CNVs) in 48 individuals with WHS. Seizure phenotype data were collected through parent-reported answers to a comprehensive questionnaire and supplemented with available medical records. Results We observed a significant correlation between the presence of an interstitial 4p deletion and lack of a seizure phenotype (Fisher's exact test p=3.59e-6). In our cohort, there were five individuals with interstitial deletions with a distal breakpoint at least 751 kbp proximal to the 4p terminus. Four of these individuals have never had an observable seizure, and the fifth individual had a single febrile seizure at the age of 1.5 years. All other individuals in our cohort whose deletions encompass the terminal 751 kbp region report having seizures typical of WHS. Additional examples from the literature corroborate these observations and further refine the candidate seizure susceptibility region to a region 197 kbp in size, starting 368 kbp from the terminus of chromosome 4. Conclusions We identify a small terminal region of chromosome 4p that represents a seizure susceptibility region. Deletion of this region in the context of WHS is sufficient for seizure occurrence.

18 February 2015 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
BCBeatrice Letizia Crippa
Beatrice Letizia Crippa
ELEyby Leon
Eyby Leon
ACAmy Calhoun
Amy Calhoun
ALAmy Lowichik
Amy Lowichik
MPMarzia Pasquali
Marzia Pasquali
NLNicola Longo
Nicola Longo

3 May 2015 in Molecular Genetics and Metabolism
Verified
Journal Article
Open access
GFGregory P. Forlenza
Gregory P. Forlenza
ACAmy Calhoun
Amy Calhoun
KBKenneth B. Beckman
Kenneth B. Beckman
THTanya Halvorsen
Tanya Halvorsen
EHElwaseila Hamdoun
Elwaseila Hamdoun
APAnna Petryk
Anna Petryk
With the completion of the Human Genome Project and advances in genomic sequencing technologies, the use of clinical molecular diagnostics has grown tremendously over the last decade. Next-generation sequencing (NGS) has overcome many of the practical roadblocks that had slowed the adoption of molecular testing for routine clinical diagnosis. In endocrinology, targeted NGS now complements biochemical testing and imaging studies. The goal of this review is to provide clinicians with a guide to the application of NGS to genetic testing for endocrine conditions, by compiling a list of established gene mutations detectable by NGS, and highlighting key phenotypic features of these disorders. As we outline in this review, the clinical utility of NGS-based molecular testing for endocrine disorders is very high. Identifying an exact genetic etiology improves understanding of the disease, provides clear explanation to families about the cause, and guides decisions about screening, prevention and/or treatment. To illustrate this approach, a case of hypophosphatasia with a pathogenic mutation in the ALPL gene detected by NGS is presented.

9 July 2014 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
ACAmy Calhoun
Amy Calhoun
GRGerald V. Raymond
Gerald V. Raymond

13 October 2016 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
Meena BalasubramanianMeena Balasubramanian
Meena Balasubramanian
HLH Lord
H Lord
SLS Levesque
S Levesque
HGH Guturu
H Guturu
FTF Thuriot
F Thuriot
DCD Chitayat
D Chitayat
Background: In 1993, Chitayat et al., reported a newborn with hyperphalangism, facial anomalies, and bronchomalacia. We identified three additional families with similar findings. Features include bilateral accessory phalanx resulting in shortened index fingers; hallux valgus; distinctive face; respiratory compromise. Objective(s): To identify the genetic aetiology of Chitayat syndrome and identify a unifying cause for this specific form of hyperphalangism. Methods: Through ongoing collaboration, we had collected patients with strikingly-similar phenotype. Trio-based exome sequencing was first performed in Patient 2 through Deciphering Developmental Disorders study. Proband-only exome sequencing had previously been independently performed in Patient 4. Following identification of a candidate gene variant in Patient 2, the same variant was subsequently confirmed from exome data in Patient 4. Sanger sequencing was used to validate this variant in Patients 1, 3; confirm paternal inheritance in Patient 5. Results: A recurrent, novel variant NM_006494.2:c.266A>G p.(Tyr89Cys) in ERF was identified in five affected individuals: de novo (patient 1, 2 and 3) and inherited from an affected father (patient 4 and 5). p.Tyr89Cys is an aromatic polar neutral to polar neutral amino acid substitution, at a highly conserved position and lies within the functionally important ETS-domain of the protein. The recurrent ERF c.266A>C p.(Tyr89Cys) variant causes Chitayat syndrome. Discussion: ERF variants have previously been associated with complex craniosynostosis. In contrast, none of the patients with the c.266A>G p.(Tyr89Cys) variant have craniosynostosis. Conclusions: We report the molecular aetiology of Chitayat syndrome and discuss potential mechanisms for this distinctive phenotype associated with the p.Tyr89Cys substitution in ERF.